Flexion Therapeutics

Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, November 6, 2020
Financial markets, Finance, Corporate finance, Financial economics, Stock market, Employee stock ownership, Fundamental analysis, Restricted stock, Stock, Executive compensation, NASDAQ, Flexion Therapeutics

BURLINGTON, Mass., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to two new employees consisting of 3,315 restricted stock units.

Key Points: 
  • BURLINGTON, Mass., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to two new employees consisting of 3,315 restricted stock units.
  • The Compensation Committee of the Board of Directors approved the grants with an effective date of November 2, 2020.
  • The restricted stock units were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The restricted stock units are subject to the terms and conditions of the Company's 2013 Equity Incentive Plan and a restricted stock unit agreement covering the grant.

Flexion Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference

Retrieved on: 
Thursday, November 5, 2020
Life sciences, Biotechnology, Flexion Therapeutics, Health sciences, Biopharmaceutical

BURLINGTON, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the 29th Annual Credit Suisse Virtual Healthcare Conference.The virtual fireside chat is scheduled to begin at 8:45 a.m.

Key Points: 
  • BURLINGTON, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the 29th Annual Credit Suisse Virtual Healthcare Conference.The virtual fireside chat is scheduled to begin at 8:45 a.m.
  • ET on Wednesday, November 11, 2020.
  • To access the live webcast of the presentation, please visit the Flexion website at http://ir.flexiontherapeutics.com .
  • Flexion Therapeutics (Nasdaq:FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of people with musculoskeletal conditions, beginning with osteoarthritis, the most common form of arthritis.

Flexion Therapeutics Reports Third-Quarter 2020 Financial Results and Recent Business Highlights

Retrieved on: 
Wednesday, November 4, 2020
Flexion Therapeutics, NASDAQ, Burlington, Vermont, Finance, Financial markets, Investment

BURLINGTON, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter ended September30, 2020.

Key Points: 
  • BURLINGTON, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter ended September30, 2020.
  • Cost of sales was $5.1million and $2.9million for the three months ended September 30, 2020 and 2019, respectively.
  • Research and development expenses were $10.1million and $20.9million for the three months ended September30, 2020 and 2019, respectively.
  • Selling, general and administrative expenses were $27.3million and $32.1million for the three months ended September30, 2020 and 2019, respectively.

Flexion Therapeutics to Report Third-Quarter 2020 Financial Results on November 4, 2020

Retrieved on: 
Thursday, October 29, 2020
Life sciences, Biotechnology, Health sciences, Flexion Therapeutics, Specialty drugs, NASDAQ, Biopharmaceutical

BURLINGTON, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its third-quarter 2020 financial results after the close of the U.S. financial markets on Wednesday, November 4, 2020.

Key Points: 
  • BURLINGTON, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its third-quarter 2020 financial results after the close of the U.S. financial markets on Wednesday, November 4, 2020.
  • The company hosted a conference call on October 13, 2020, in conjunction with reporting preliminary third-quarter net sales.
  • A replay of that call is available on Flexions corporate website: https://ir.flexiont h erapeutics.com/events-and-presentations .
  • Flexion Therapeutics(Nasdaq:FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, the most common form of arthritis.

Flexion Therapeutics Announces Preliminary Third-Quarter 2020 ZILRETTA® Net Sales of Approximately $23.6 Million

Retrieved on: 
Tuesday, October 13, 2020
RTT, Medical specialties, Steroids, Glucocorticoids, Acetonides, Organofluorides, Chemical compounds, Rheumatology, Flexion Therapeutics, Triamcinolone acetonide, Triamcinolone, Joint injection

BURLINGTON, Mass., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced preliminary ZILRETTA(triamcinolone acetonide extended-release injectable suspension) net sales of $23.6 million for the quarter ended September 30, 2020.

Key Points: 
  • BURLINGTON, Mass., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced preliminary ZILRETTA(triamcinolone acetonide extended-release injectable suspension) net sales of $23.6 million for the quarter ended September 30, 2020.
  • Each year, healthcare providers administer approximately eight million intra-articular injections to help patients manage osteoarthritis knee pain.
  • 77% of purchasing accounts (3,153) placed at least one reorder up from 2,983 accounts that had reordered ZILRETTA as of June 30, 2020.
  • Accounts that had purchased more than 50 ZILRETTA units accounted for 258,562 of the total 295,641 ZILRETTA units purchased.

Flexion Therapeutics to Present at the 2020 Cell & Gene Virtual Meeting on the Mesa

Retrieved on: 
Thursday, October 8, 2020
Branches of biology, Biology, Clinical medicine, Arthritis, Medical genetics, Flexion Therapeutics, Emerging technologies, Osteoarthritis, Gene therapy, Interleukin 1 receptor antagonist, Osteochondritis dissecans

BURLINGTON, Mass., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc.(Nasdaq:FLXN) announced today thatAdam Muzikant, Ph.D., Senior Vice President, Business Development, will present at the annual 2020 Cell & Gene Virtual Meeting on the Mesa.

Key Points: 
  • BURLINGTON, Mass., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc.(Nasdaq:FLXN) announced today thatAdam Muzikant, Ph.D., Senior Vice President, Business Development, will present at the annual 2020 Cell & Gene Virtual Meeting on the Mesa.
  • Dr. Muzikant will provide a review of FX201, an investigational, intra-articular, IL-1Ra gene therapy product candidate in clinical development for the treatment of osteoarthritis (OA).
  • The trial is intended to test low, mid and high doses of FX201 in cohorts of five to eight patients.
  • Organized by theAlliance for Regenerative Medicine, the 2020 Cell & Gene Meeting on the Mesa will be delivered in a virtual format over the course of five days beginning on October 12.

Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, October 2, 2020
Financial markets, Finance, Corporate finance, Financial economics, Stock market, Employee stock ownership, Fundamental analysis, Restricted stock, Executive compensation, Stock, Flexion Therapeutics, NASDAQ

BURLINGTON, Mass., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to two new employees consisting of 3,315 restricted stock units.

Key Points: 
  • BURLINGTON, Mass., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to two new employees consisting of 3,315 restricted stock units.
  • The Compensation Committee of the Board of Directors approved the grants with an effective date of October 1, 2020.
  • The restricted stock units were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The restricted stock units are subject to the terms and conditions of the Company's 2013 Equity Incentive Plan and a restricted stock unit agreement covering the grant.

Flexion Therapeutics to Present at the H.C. Wainwright Virtual Healthcare Conference

Retrieved on: 
Wednesday, September 9, 2020
Flexion Therapeutics

BURLINGTON, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the H.C. Wainwright Virtual Healthcare Conference.The virtual fireside chat is scheduled to begin at 10:00 a.m.

Key Points: 
  • BURLINGTON, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the H.C. Wainwright Virtual Healthcare Conference.The virtual fireside chat is scheduled to begin at 10:00 a.m.
  • ET on Tuesday, September 15, 2020.
  • To access the live webcast of the presentation, please visit the Flexion website at http://ir.flexiontherapeutics.com .
  • Flexion Therapeutics (Nasdaq:FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of people with musculoskeletal conditions, beginning with osteoarthritis, the most common form of arthritis.

Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, September 4, 2020
Financial markets, Finance, Corporate finance, Financial economics, Stock market, Employee stock ownership, Fundamental analysis, Restricted stock, Executive compensation, Stock, Flexion Therapeutics, NASDAQ

BURLINGTON, Mass., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to three new employees consisting of 13,940 restricted stock units.

Key Points: 
  • BURLINGTON, Mass., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to three new employees consisting of 13,940 restricted stock units.
  • The Compensation Committee of the Board of Directors approved the grants with an effective date of September 1, 2020.
  • The restricted stock units were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The restricted stock units are subject to the terms and conditions of the Company's 2013 Equity Incentive Plan and a restricted stock unit agreement covering the grant.

Flexion Therapeutics to Present at the Wells Fargo 2020 Virtual Healthcare Conference

Retrieved on: 
Thursday, September 3, 2020
Life sciences, Articles, Biotechnology, Flexion Therapeutics, Biopharmaceutical

BURLINGTON, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Wells Fargo 2020 Virtual Healthcare Conference.The virtual fireside chat is scheduled to begin at 10:40 a.m.

Key Points: 
  • BURLINGTON, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Wells Fargo 2020 Virtual Healthcare Conference.The virtual fireside chat is scheduled to begin at 10:40 a.m.
  • ET on Wednesday, September 9, 2020.
  • To access the live webcast of the presentation, please visit the Flexion website at http://ir.flexiontherapeutics.com .
  • Flexion Therapeutics (Nasdaq:FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of people with musculoskeletal conditions, beginning with osteoarthritis, the most common form of arthritis.